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Abstract
The emergence of a novel coronavirus and coronavirus disease 2019 (COVID-19) represents a challenge to global healthcare. In the
past 20 years, this is the third coronavirus that jumped the species barrier and infected humans. It is highly contagious but associ-
ated with low pathogenicity. First identified in Wuhan, China, a city of over 11 million, the disease has since spread to every continent
except Antarctica. About 15% to 20% of all cases may be called severe, and it is believed many cases are asymptomatic. The average age
of a person with COVID has been reported as 49 years. Worse outcomes are associated with geriatric populations and those with un-
derlying diseases such as cardiovascular, respiratory disorders, and/or diabetes. The coronavirus, like other coronaviruses, is highly
contagious and has a latency period of about 14 days. Most patients present with fever and a dry cough, but fever may be absent.
Differential diagnosis can be challenging since influenza may present with similar symptoms. Chest radiography or computed to-
mography may be used to find evidence of secondary pneumonia. Nosocomial infection is of concern, and it has been reported that
3.8% of all cases with COVID-19 in that country involve healthcare workers in China. Most patients have mild disease, and supportive
care suffices. A variety of repurposed and investigational drugs are being evaluated. There are currently no antiviral therapies or
vaccines, even if many therapies are proposed. Hand hygiene, social distancing, and scientifically sound information are the best
strategies at the moment to combat this epidemic.
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1. Context
In February 2018, the World Health Organization
(WHO) published its Blueprint List of priority diseases that
includes Severe Acute Respiratory Syndrome (SARS), Mid-
dle Eastern Respiratory Syndrome (MERS), and a to-be-
identified disease listed in its report as Disease X. Disease
X was defined as a new disease with epidemic or pandemic
potential caused by an unknown pathogen (1). The emer-
gence of the novel coronavirus in 2019, now known as SARS-
CoV-2 or COVID-19, may be the Disease X. In our era of glob-
alization, mass travel and relatively porous borders cause a
lot of concerns. This virus is the seventh identified form of
coronavirus that can cause respiratory disease in humans
(2). Its emergence should be of no surprise such that this is
the third example of a zoonotic coronavirus that jumped
the species barrier to infect numerous humans across the
globe in the past 20 years (3), the others include SARS in
2003 and MERS in 2015 (4-6).
For most adults and children with good health, the
virus manifests with mild flu-like symptoms and it appears
many infected individuals are asymptomatic or have such
mild symptoms that they do not seek medical care. For
vulnerable populations and those with underlying health
problems, the illness may be severe, resulting in multiple
organ failure and death (7). Our current understanding is
that the routine latency period for COVID-19 takes three to
seven days with a maximum of 14 days (8, 9). It appears that
unlike SARS, COVID-19 can be contagious even during the
latency period (8). At first, it was thought that pediatric pa-
tients did not get COVID-19 or that their immune systems
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were particularly robust at holding back the pathogen, but
a study of 391 individuals and their close contacts (n = 1,286)
found that children under the age of 10 were just as likely
to contract the COVID-19 as people of other age groups and
that about 7% of these children exposed to the virus be-
came infected (10). Until April, no deaths have been re-
ported in any patient younger than nine years (11). Unfor-
tunately, a few studies reported the deaths of newborns, in-
fants, and toddlers (12-14). It is not yet clear how efficient
the children are at transmitting of SARS-CoV-2 (10).
The aim of this study was to summarize the current un-
derstanding of the clinically relevant findings on COVID-19.
2. COVID-19 in the Context of Other Coronaviruses
Human coronaviruses are common, enveloped RNA
viruses that cause up to a third of all common colds in
adults (15). Low pathogenic types of the virus mainly af-
fect the upper respiratory system and produce mild symp-
toms. In contrast, highly pathogenic types, such as SARS
and MERS, can cause lower-respiratory tract infections and
lead to secondary life-threatening bacterial pneumonia
(16). In cases of highly pathogenic SARS or MERS infec-
tion, the virus replicates rapidly with massive infiltration
of inflammatory cells and an escalated pro-inflammatory
cytokine response, known as cytokine storm, which is an
aberrant immunological response (16, 17). A suppressed
immune system or inadequate immune response may fa-
cilitate viral replication and attendant tissue destruction.
On the other hand, an over activated inflammatory and im-
munological defense may set the stage of immunopatholo-
gies (18). The SARS-CoV-2 is a beta-coronavirus of low
pathogenicity; however, it has a phylogenetic similarity to
the SARS (19). The SARS-CoV-2 is a non-segmented, positive-
sense, single-stranded RNA virus with a nucleocapsid com-
posed of genomic RNA and a phosphorylated nucleocapsid
protein. The virion is located in the phospholipid bilayers
and is covered by spike proteins. The virus family takes its
name from the “crowns” that appear on the virus (Figure
1) (3). These surface glycoprotein spikes are thought to be
crucial for the virus to bind to the host, possibly restricting
the range of potential hosts (5). Genomic sequencing of
SARS-Cov2 was performed on bronchoalveolar lavage fluid,
and cultured isolates from nine confirmed COVID-19 inpa-
tients (20). The ten genome sequences that resulted had
over 99.98% sequence identity and 88% similarity to coro-
navirus sequences obtained from two bats with SARS but
were less similar to MERS (~ 50%) (20). The SARS-Cov2 is in
the beta-coronavirus genus in the subgenus Sarbecovirus
with sufficient genetic originality to be considered a novel
virus (20). The genetic sequences of the novel coronavirus
have been published on the Global Initiative on Sharing All
Influenza Data (GISAID) at gisaid.org (3).
The COVID-19 virus is enveloped within round or oval
particles having a diameter of about 60 to 140 nm. As coro-
naviruses generally are ubiquitous pathogens, many peo-
ple already have natural corresponding antibodies. For ex-
ample, it has been estimated that 30% to 60% of the main-
land Chinese population has some forms of anti-COVID-19
antibodies (18). It appears that, like SARS, SARS-Cov2 recep-
tor is the angiotensin-converting enzyme 2 (ACE2) receptor
that is highly expressed on the epithelium of the airways,
which mediates cellular entry (8, 20). The SARS-Cov2 repli-
cates more rapidly in human airway epithelial cells than in
standard-tissue cultures (19). COVID-19 seems to be more
readily transmissible than SARS or MERS (11).
The SARS-Cov2 was first identified in the city of Wuhan,
China in December 2019 (21). Wuhan is a large, landlocked
city of about 11 million inhabitants and is the capital of
Hubei Province. Compared to SARS and MERS, COVID-19 is
associated with milder illness and lower fatality rates; the
case fatality rate for SARS is 9.5%, and MERS is 34.4% (6).
The SARS originated from China, and it may be that
lessons learned from that epidemic played an important
role in Chinese response to COVID-19. China did not re-
port SARS to the WHO until there were 300 confirmed
cases, and five deaths had occurred. In contrast, China re-
ported COVID-19 to WHO with just 27 confirmed cases and
before any fatalities occurred (11). Thus, the lag time from
pathogen identification to WHO reporting went from two
months with SARS to a week with COVID-19 (11). China also
acted quickly to impose travel restrictions as the outbreak
of COVID-19 coincided with Christian New Year, the most
important holiday of the year and associated with par-
ties, large gatherings, and travel (11). Even outside Wuhan,
tourist attractions such as the Forbidden City in Beijing
and Disneyland parks in Shanghai and Hong Kong were
closed quickly (22).
3. The COVID-19 Disease Pyramid
The extent of subclinical COVID-19 presentation re-
mains unknown, so it is not yet possible to construct a
“disease pyramid” to evaluate the relationship of asymp-
tomatic to mild to moderate and severe cases (6). Deaths
seem to occur in geriatric or other vulnerable patients
and/or immunocompromised patients and relate to acute
respiratory distress syndrome (2). It has been estimated
that about 15% to 20% of cases with COVID-19 may be cat-
egorized as severe, but that may be an inaccurate assess-
ment because a number of asymptomatic cases which do
not seek medical attention are unknown and may even
compose the majority of all cases (2).
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Figure 1. COVID-19 structure
Early epidemiological data from China have found that
the average age at which a person contracts COVID-19 is
49 years (21), and most cases occur in people between the
ages of 30 and 79 years (11). Only about 1% of cases oc-
curred in patients under the age of nine (11). Of all con-
firmed cases, 81% could be described as “mild” (11). In one
of the first epidemiological reports from China, of 41 hos-
pitalized patients in the city of Wuhan, 30/41 were men and
32% had an underlying disease (17). A later study (n = 1,099)
on laboratory-confirmed cases with COVID-19 showed that
of 552 hospitals throughout China, 58.1% of patients were
men, and the median age of all patients was 47 years (23).
The composite endpoint, met by 6.1% of patients (n = 67),
was the admission to intensive care unit (ICU), use of me-
chanical ventilation, or death (23).
Based on a study on 1,099 confirmed cases with COVID-
19, the median incubation period of the disease is 4 days,
with an interquartile range of 2 to 7 days (23). The main
symptoms of COVID-19 are fever, dry cough, and dyspnea. It
should be noted that fever does not necessarily need to be
present. Nasal congestion and rhinorrhea are not present
in all patients but have been reported. Patients with se-
vere disease may exhibit weakened breath sounds (9). Dif-
ferential diagnosis can be challenging because many viral
respiratory diseases produce similar symptoms (24). This
is further complicated by the fact that bacterial pneumo-
nia, which may be secondary to COVID-19, may be caused
by other factors (24).
4. A Short Timeline of COVID-19
For many years, the coronavirus was regarded as a
ubiquitous but clinically inconsequential pathogen asso-
ciated with the annoying but hardly dangerous common
cold (5). The versatile coronavirus has infected a range of
animal species and zoonotic transmission, although rare
in general, has played a major role in the emergence of
novel human coronaviruses and ensuing epidemics (25).
The first patient with COVID-19 was one in a cluster of pa-
tients suffering from “pneumonia of unknown origin” in
early December 2019 (26). Patient zero was likely to have
been infected at the Hua’nan Seafood Wholesale Market in
Wuhan (4). Although nominally a wholesale market for
seafood, the market actually carried a wide range of living
and dead wild animals (26). Bats, which are sold for human
consumption in Wuhan, have been implicated as a possi-
ble host for the COVID-19 virus but it is also possible that
some other intermediate animals were involved (17). Fur-
ther evidence for bats as the possible animal host was ob-
tained when a live SARS-related coronavirus was isolated
from a fecal sample from a bat with 99.9% whole genome
sequence identity to SARS was identified in horseshoe bats
(27). Contact tracing revealed that many of those with this
mysterious pneumonia had recently gone to the Hua’nan
Seafood Wholesale Market. By the time, the first fatality
was reported on January 1, 2020, the market was closed for
decontamination and other wildlife markets in the area
were closed (26).
The pathogen was isolated on January 7, 2020, which
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was initially named “2019 novel coronavirus” or 2019-nCoV
and the disease was named on January 12, 2020, by WHO
as the coronavirus disease of 2019 or COVID-19 (9). The iso-
lation of the virus allowed Chinese scientists to develop a
rapid testing method for point-of-care (21). The first fatal-
ity in a person confirmed to have the SARS-CoV2 occurred
on January 11, 2020. On January 12, 2019, a whole genome
sequence was shared with WHO (21), and by January 13,
2020, the disease had spread to Thailand with other cases
soon reported in Japan, Korea, Vietnam, Singapore, Taiwan,
Hong Kong, Macau, and the United States (21). On January
30, 2020, WHO declared it a public health emergency of in-
ternational concern (26).
Wenliang, a physician in China, was arrested when he
raised questions about COVID-19 on social media. He con-
tracted the virus and died on February 7, 2020 (28). By
February 11, China had launched its so-called “wartime con-
trol measures” to put cities on lockdown, essentially re-
stricting the movements of an estimated 760 million cit-
izens (28). Flights and trains in and out of Wuhan were
canceled, schools were closed, and even private cars were
restricted (2). Because of Christian New Year festivities,
which occur over many days, it is estimated that about 5
million people who normally resided in Wuhan were away
from home when the quarantine was announced (2).
The disease spread with 75,748 confirmed cases with
COVID-19 was reported in 28 countries by February 20,
2020, but the vast majority of those cases (~ 99%) were in
mainland China (26). Fourteen cases were reported in the
United States on February 21, 2020, and by March 5, 2020,
the United States had 150 confirmed cases of COVID-19 and
11 deaths (29). February 26, 2020, marked the first date
where there were more confirmed new cases with COVID-
19 outside of mainland China than within (30). The disease
was spread to every continent except Antarctica. By March
5, 2020, there were 93,090 confirmed cases with COVID-19
around the world with 80,422 in China; 2,502 in Italy; 212
in France; 24 in Sweden; 16 in Iceland; and 8 in Belgium,
highlighting the rapid spread of the disease (31). At the mo-
ment, the world number of diagnosed cases is over 1.5 Mil-
lion.
5. Transmissibility
Coronaviruses, in general, tend to be highly conta-
gious; in one case during the SARS epidemic, one person
traveling from Hong Kong to Toronto could be traced to
128 cases with SARS in a local hospital; the same occurred
with MERS where one person from Saudi Arabia who vis-
ited South Korea was associated with 186 cases with MERS
(6). With SARS and MERS, most infections were the result of
nosocomial transmission within the hospital setting, and
this suggests that there is likely high risk of nosocomial
transmission of COVID-19 (6). COVID-19 disease transmis-
sion is thought to occur by droplets in liquid or aerosol
form from one infected person to another person (4). Evi-
dence is emerging that asymptomatic individuals infected
with COVID-19 may be capable of transmitting the disease
(32). There is also some evidence that patients may con-
tinue to shed the virus after recovery (32). Additionally, it
may be that “super-spreader” events may occur in which
one infected individual may be able to transmit the virus
to a disproportionately large group of people (6). While
the original epidemic centered on Wuhan and the seafood
market, today at least 72% of people newly infected with
COVID-19 have no ties to Wuhan province or its residents
(23).
The basic reproductive number (R0) is defined as the
expected number of cases that are directly generated by
one case among a population of susceptible individuals.
The R0 for COVID-19 is approximately 1.4 to 2.5 (2, 3). From a
study conducted in China from December 31, 2019, to Jan-
uary 28, 2020, the R0 was 2.68 (95% confidence interval,
2.47 to 2.86) and the epidemic population doubled every
6.4 days (95% confidence interval, 5.8 to 7.2) (33).
Since COVID-19 can be efficiently transmitted from hu-
man to human, an epidemic is made possible; globaliza-
tion and increased travel allows for the pandemic. The fact
that COVID-19 is overall associated with milder symptoms
than other viruses may mean it will spread faster (6). For
example, during the H1N1 (swine flu) epidemic, the virus
caused relatively minor upper respiratory symptoms but
spread extensively. By contrast, the H7N9 (avian flu) virus
was associated with a far more virulent lower-respiratory
tract infection and had a 40% fatality rate but was not as
readily transmissible (6). The lower fatality rate exhibited
by COVID-19 allows for the preservation of infected hosts,
which can increase the potential for continued transmis-
sion.
People who may have been exposed to COVID-19 should
be observed for 14 days, during which time they should
have minimal contact with other people. The 14-day win-
dow is counted forward from the last day of possible expo-
sure (9). Although patients with confirmed cases of COVID-
19 may be encouraged to wear N95 protective masks, there
is little evidence that masks worn by unexposed people
serve any protective purpose (9). When a suspected person
with or confirmed case with COVID-19 requires hospitaliza-
tion, the patient should as much as possible travel in a pri-
vate vehicle, wear a mask, and keep distant from other in-
dividuals; the hospital should be alerted of the arrival of a
possible or confirmed patient with COVID-19 before the pa-
tient is brought to the facility (9).
If a patient is isolated at home, he or she should stay in
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a well-ventilated single room cleaned multiple times a day
with a solution of 500 mg/L chlorine disinfectant (9). Tow-
els, silverware, dishes, and other personal items should be
single-use only or thoroughly washed after each use (9).
Thorough and frequent hand-washing with soap and wa-
ter is recommended for both patients and households. If
a person isolated at home does not improve quickly or if
symptoms worsen, medical care may be warranted (9).
6. Clinical Course and Diagnosis
In a study of 80 patients with diagnosed COVID-19 in
China from January to February 2020, the most common
clinical presentations included elevated body temperature
(76%) and coughing (73%). The clinical trajectory for adults
and children in otherwise good health often involves mild
symptoms and it is thought that many are unaware they
have the virus. In vulnerable patients, the elderly, or those
with underlying diseases, pneumonia, or other severe and
potentially life-threatening respiratory symptoms may de-
velop (34). In a study of 1,099 confirmed cases with COVID-
19 in Chinese hospitals, 43.8% of patients had fever upon
admission to the hospital and 88.7% developed a fever dur-
ing their hospital stay; 67.8% had a cough, and 3.8% had di-
arrhea (23).
Diagnosis is based on case presentation (fever and
symptoms of respiratory illness) combined with an epi-
demiological link to the virus in the past 14 days (34). As the
disease spreads, this epidemiologic link becomes increas-
ingly tenuous. It should also be noted that not all patients
develop a fever. The standard test is a nucleic acid test used
with respiratory or serum samples, which can confirm or
refute COVID-19 infection in about four to six hours (7, 9).
Chest radiography or chest computed tomography
(CT) can be used to find evidence of pneumonia, which
typically presents in the form of bilateral, ground-glass
opacity in more than one lobe and with sub-segmental ar-
eas of consolidation (35). In fact, chest CT or radiography
has been recommended to confirm COVID-19 (9). A study
of 80 patients with COVID-19 diagnosed between January
and February 2020, found that on chest CT, 91% had evi-
dence of ground-glass opacity, 63% had consolidation, and
59% showed interlobular septal thickening. Most lesions
were multiple with an average of 12 ± 6 segments (35).
In this study, the average pulmonary inflammation index
(PII) was 34% ± 20% and could be significantly correlated
with lymphocyte count, monocyte count, C-reactive pro-
tein levels, procalcitonin, days from onset of illness, and
body temperature (P < 0.05) (35). In a study of 1,099 pa-
tients with COVID-19, 56.4% had evidence of ground-glass
opacity on chest CT, which was considered the most com-
mon radiologic finding in the confirmed patients (23). It
must be noted in this context that patients without severe
disease may have normal chest CT or radiography. In fact,
2.9% of patients with severe COVID-19 had normal chest im-
ages and 17.9% of those with milder forms of COVID-19 had
normal images (23).
In a study of chest CTs in patients with COVID-19 (n = 21),
3/21 patients had normal chest CTs. Of the patients with ab-
normal chest CTs, 86% had the disease, affecting more than
one lobe and 38% had the disease in all five lobes (36). The
mean total lung severity score was 9.9 (range 0 to 19) and
the patient with the highest score in this study required
hospitalization in the ICU (36). A follow-up CT scan was
carried out in these patients at a mean of 2.5 days later
(range 1 to 4 days) and no patient showed severe progres-
sion and none showed interval improvement; the majority
(63%) showed signs of mild progression and one of the pa-
tients who had a normal CT scan for the first time exhibited
one peripheral ground-glass lesion on a CT scan three days
later (36).
7. Vulnerable Populations
Most people who are infected with COVID-19 recover.
Severe morbidity and mortality appear to occur in the vul-
nerable populations who contract COVID-19.
7.1. Neonates
In early February 2020, China reported the infection in
a neonate 30 hours old (7). This caused China to launch a
special initiative in its neonatal intensive care units with
specific diagnostic and discharge criteria (7). Neonates
with risk factors for COVID-19 such as family history or ex-
posure should be isolated in a single room for 14 days (7).
If an infant had previously shared a room with other ba-
bies, the others in the group should also be isolated until
COVID-19 can be definitively ruled out (7). Any sort of dis-
ease outbreak in pediatric wards will be associated with ex-
treme psychological distress in parents. As much as possi-
ble, social workers or trained psychological staff should be
available to counsel parents and family members in case of
any sort of viral outbreak in the NICU or in pediatric care
centers (7).
7.2. Pediatric Patients
The COVID-19 does not seem to be prevalent in pedi-
atric patients but at least 20 pediatric cases have been re-
ported in China. A study on 10 of those patients found
their age at onset of COVID-19 ranged from 112 days to 17
years and clinical presentation was similar to that of adults
(24). Some children are afebrile and when fever is present,
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it is typically low. With disease progression, pediatric pa-
tients can present with shortness of breath, cyanotic, rest-
less, fatigued, lethargic, and may exhibit poor feeding or
show signs of systemic toxicity (24). Children most at risk
of COVID-19 appear to be those related to cluster outbreaks
or those who had contact with an infected person or recent
travel or residence in Wuhan (24).
7.3. Pregnant Patients
Pregnant women should be screened, tested, and pro-
vided with care in isolation, if required, and adaptations
may need to be made to accommodate these persons. The
use of any investigational research agents or therapies in
pregnant patients requires careful consideration of the
safety of mother and fetus and should involve the ethics
committee and obstetric specialists (37). Pregnant women
with COVID-19 are at risk of hypoxemia that may lead to in-
trauterine asphyxia and possibly premature delivery (24).
7.4. Elderly Patients and Patients with Underlying Diseases
Older patients and those with underlying chronic con-
ditions, such as cardiovascular and respiratory chronic dis-
eases, diabetes, or malignancy, are considered vulnerable.
Geriatric patients and/or those with underlying disease are
at increased risk for death from acute respiratory distress
(2, 9). Case-fatality rates among patients in otherwise good
health are about 2.3% (11). Among patients ≥ 80 years of
age, the case-fatality rate is 14.8%, and it is 8.0% for those
between the ages of 70 and 79 years. For critical cases, the
case-fatality rate has been reported at 49.0% (11). Among
those with underlying disease (all ages), the case-fatality
rates are 10.5% for cardiovascular diseases, 7.3% for dia-
betes mellitus, 6.3% for chronic respiratory disease, 6.0%
for hypertensives, and 5.6% for oncology patients (11).
It should be noted that the use of case-fatality rates in
describing this epidemic has been criticized because case-
fatality rates tend to be biased toward the most severe (hos-
pitalized) patients and ignore asymptomatic cases (38).
That is, they may suggest more alarming outcomes than
are likely. Furthermore, it must be recognized that our
data, to date, are based on very small patient populations
and may not reflect the future course of the disease (39).
7.5. Healthcare Professionals
The COVID-19 appears to follow the pattern of the prior
coronavirus epidemics of SARS and MERS such that noso-
comial infection is of great concern (21). In mid-February
2020, the Centers for Disease Control and Prevention in
China (CDC-China) reported that 3.8% of all COVID-19 cases
were in healthcare workers and, of this population, 63%
resided in Wuhan and 14.8% of these cases were severe
or critical. Five cases with COVID-19 in Wuhan healthcare
workers were fatal (11). Healthcare workers have been ad-
vised to wear medical overalls, caps, and surgical masks
when triaging patients (24). Those working in the pul-
monary clinics, infectious disease departments, isolation
wards, emergency rooms, or other similar settings should
wear medical overalls, caps, disposable isolation clothing,
masks, goggles, and a face shield. A respiratory hood may
be advised in some situations to prevent splash contamina-
tion e.g. when intubating an infected patient is required
(24). All protective gear should be done and removed in
strict accordance with the hospital’s on/off protocols, and
protective clothing should not be worn outside of the des-
ignated area to prevent cross-contamination (24).
Professionalism and compassion make us remember
that healthcare providers at the epicenter of this crisis
face tremendous and unprecedented problems ranging
from their elevated risk of infection to overwork, frustra-
tion, shortage of needed supplies or equipment, unknown
aspects of the COVID-19 virus, isolation from family and
friends, physical and mental exhaustion, and the stress of
dealing with patients in crisis (40). Mental health symp-
toms such as stress, anxiety, insomnia, depression, anger,
and fearfulness not only are detrimental to healthcare
professionals, they may also impede their ability to make
sound clinical decisions in life-and-death frontline situa-
tions (40). Hospitals in Wuhan have initiated special shift
scheduling so that clinicians can alternate time in high-
stress positions and a psychological support team has been
set up to provide special interventions, educational efforts,
and a hotline for healthcare workers in distress (40).
8. An Overview of Treatment Strategies
Overall, the management consists of homeostasis
management and the initiation of respiratory support if
needed (21). Antimicrobial drugs are only helpful to pa-
tients with likely or confirmed bacterial infections and
their empirical use is not recommended (21). The role of an-
tiviral medications to treat COVID-19 is not clear, so far (21).
Treatment should be supportive care with the patient iso-
lated and monitored for vital signs. It is important that pa-
tients stay appropriately hydrated and are well-nourished.
Routine blood studies, including C-reactive protein, and
organ function should be monitored with other tests as
deemed appropriate. Some patients may require oxygen
therapy, non-invasive ventilation, or invasive ventilation
(41). Extracorporeal membrane oxygenation should be
considered in patients with refractory hypoxemia (9). A va-
riety of repurposed drugs, as well as investigational drugs,
have been identified for possible use. Screening National
Medical Products Administrations approved drug libraries
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and other chemical libraries have been identified as novel
agents. Hundreds of clinical trials, including those in-
volving remdesivir, chloroquine, favipiravir, convalescent
plasma, and others, are planned or on the way (42).
At present, there is no evidence supporting any drug
therapy for the patients (9). The use of antipyretic drugs
has been discussed, with some criticism on the use of anti-
inflammatory medicines that could increase the risk of
pulmonary infections. At the moment, there are no data
in the literature related to this and, following the current
literature, all the antipyretic drugs may be used safely (43).
Of course, they should be used with the usual recommen-
dations (44), but especially Ibuprofen seems very safe (45).
There are no antiviral therapies or vaccines for COVID-
19 (41). In fact, there is no evidence from any random-
ized clinical studies to support any particular anti-COVID-
19 therapy (37). Short-term corticosteroids have been used
to treat SARS and MERS but current WHO guidelines advise
against the use of corticosteroids for COVID-19 unless there
are alternate indications for their use (43). Corticosteroids
not only suppress pulmonary inflammation but also may
suppress the immune response and pathogen clearance
(46). Based on a meta-analysis of various treatment modal-
ities for SARS, corticosteroid use in patients with SARS was
found harmful (47). In a meta-analysis of 6,548 influenza
patients with pneumonia, the risk ratio for mortality in-
creased up to 1.8 (95% confidence interval, 1.3 - 2.4, P ≤
0.001) among those administered corticosteroids (48). It
should be noted that antibiotics are recommended for pa-
tients with COVID-19 in case of a bacterial infection (22).
Chloroquine phosphate, a drug that has been used
globally for over 70 years to treat malaria, has been shown
to have prominent efficacy and safety in studies in China
for the treatment of pneumonia associated with COVID-
19 (49). In in vitro studies, low-micromolar chloroquine
concentrations were able to block COVID-19 (49). The half-
maximum effective concentration (EC50) for chloroquine
is 1.13 µM. The half-cytotoxic concentration (CC50) is >100
µM (49). In early studies in several Chinese hospitals
(n = 100), chloroquine has inhibited the exacerbation of
pneumonia, improved lung imaging, promoted a virus-
negative conversion, and shortened the course of the dis-
ease to a greater extent than control treatment (47). No se-
vere adverse effects were reported (49). Chloroquine has
broad-spectrum antiviral activity; for example, it increases
the endosomal pH necessary for virus and cell fusion and
likely interferes with the glycosylation of cellular receptors
of certain viruses (49-51).
Sepsis has been reported among patients with COVID-
19. Since septic shock in these patients may be more likely
resulted from increased intrathoracic pressure during in-
vasive ventilation, which impedes cardiac filling, this type
of septic shock differs from the vasoplegic shock and heart
failure that occurs in other patients (46). Although corti-
costeroids are occasionally used in the treatment of sepsis,
it is not clear if they would be effective in treating sepsis
related to COVID-19 (46).
9. Emerging Lessons from COVID-19
In a retrospective analysis of data on 183 consecutive
patients with confirmed cases of the novel coronavirus in
the Tongji hospital in China, from the period of January 1
to February 3, 2020, it was found that coagulation param-
eters may be important predictors of disease trajectory.52
Blood samples for coagulation tests were collected on ad-
mission and during the hospitalization period, including
prothrombin time (PT), activated partial thromboplastin
time (APTT), antithrombin activity (AT), fibrinogen, fibrin
degradation product (FDP), and D-dimer scores. The mean
age in this population was 54.1 years (range 14 to 94) and
41.0% entered the hospital with a chronic condition such as
cardiovascular disease, respiratory disorder, chronic liver
or kidney disease, and malignancy. On February 13, 2020,
42.6% of the patients in this study were discharged, 45.9%
remained hospitalized in stable condition, and 11.5% (n =
21) died (52). The investigators examined anticoagulation
parameters between those who survived and the deceased.
On admission to the hospital, the non-survivors had sig-
nificantly lower PT and APTT times and higher D-dimer
and FDP levels than did survivors. Toward the end of the
hospitalization, fibrinogen and AT levels were significantly
lower in non-survivors. This suggests that coagulation pa-
rameters may play a predictive role in survival (52). Dis-
seminated intravascular coagulation (DIC) was observed in
many deceased patients and DIC may be caused due to sep-
sis (52).
In other lessons from the COVID-19, it is advisable for
public health efforts to educate people about respiratory
hygiene. The mouth should be covered when sneezing
or coughing and the tissue or paper towel used disposed
of immediately, followed by vigorous hand washing (9).
People who sneeze and cough often should wear masks
to protect those around them (9). Public health messages
should also stress the importance (and simplicity) of hand
hygiene.
China was able to mobilize rapidly to meet this chal-
lenge by isolating the pathogen, creating test protocols
and kits, and building dedicated hospitals (53). Developed
nations have the resources to meet these challenges, which
may be devastating to developing nations with inadequate
healthcare resources, lack of funds, and possibly other fac-
tors such as ongoing wars or conflicts. For such nations,
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it is crucial to identify cases of the virus rapidly and accu-
rately and to isolate those who might otherwise transmit
the disease. This may involve prohibiting travel into or out
of the country.
Social media and journalism have been both a bless-
ing and a curse in this crisis. Sensationalist reporting, mis-
information, politicization of the crisis, and irresponsible
messaging may fan the flames of normal watchful concern
into an unjustified panic. On the other hand, the rapid
sharing of information and accurate reporting have done
much to allay fears and allow for a tempered and effective
response.
10. Discussion
Reports from China suggest that COVID-19 spreads
rapidly and the severity of the illness varies among pa-
tients from asymptomatic to potentially life-threatening.
Moreover, many patients have no fever or abnormal radi-
ological findings (23). Although compared with SARS and
MERS, COVID-19 appears to be a milder illness that is more
readily transmitted. Since COVID-19 is readily transmitted,
higher outbreaks, cases, and fatalities may be expected (18).
The challenges to meeting any sort of epidemic of this
nature include tamping the rapid spread of the disease, re-
ducing the high risk of nosocomial infection, tempering
the unpredictability of impact, and delivering adequate
healthcare resources in a timely fashion (42). In conditions
with mild or even moderate symptoms but without proper
testing, it can be difficult to differentiate a common cold,
influenza, and COVID-19. Nosocomial spread of the disease
is challenging because healthcare workers may have ex-
tended exposure to the infection (53). This can be associ-
ated with a shortage of workers, excessive patient loads, in-
adequate care for patients, and psychological stress on the
clinicians (53).
The nature of the coronavirus and other pathogens in
an era of globalization means that healthcare providers,
government authorities, and the public must equip them-
selves to face similar pandemics in the future. The over-
all goal is to use solid information rather than sensation-
alism to respond rapidly and effectively address the cri-
sis. Currently, the WHO has issued surveillance definitions
and guidelines for the disease that are not discussed here
and are likely subjected to updating and modification as
COVID-19 is better understood (37).
The COVID-19 is a novel virus with a high potential for
rapid spread, especially in our globalized society. However,
all of society, especially our “communicators” in the press,
media, and healthcare systems, should present scientifi-
cally grounded and balanced reporting on the virus rather
than sensationalistic stories or histrionic speculation. It is
not as if our world is facing a new outbreak of the bubonic
plague with no remedies in sight. Rather, we are facing
a new virus with a high potential for spread but it has a
low potential for being lethal in the normal population.
Therefore, announcement, treatment, isolation, and other
preventive steps should be taken to stop its spread. These
steps are necessary and important, even if they have ad-
verse economic consequences. However, perspective must
be maintained and scientific approaches should be consid-
ered when describing, discussing, or dealing with COVID-
19.
11. Conclusion
The outbreak of COVID-19 in China at the end of Decem-
ber 2019 has led to a pandemic with numerous infections
and some fatalities. This novel coronavirus is spreading
rapidly but it is not fatal to most people in otherwise good
health who contract the virus. The rapid spread of the virus
may be due in part to the fact that it is transmissible even in
the latency period and many people have subclinical infec-
tions. Fatalities due to COVID-19 appear to be concentrated
in vulnerable populations, such as the elderly and those
with underlying chronic diseases. Precautions in the gen-
eral population (rigorous hand hygiene), isolation of those
exposed to the disease for a 14-day period, and care in the
clinical environment to protect healthcare workers with
protective equipment are being used to reduce the spread
of COVID-19. In fact, COVID-19 is an evolving epidemic that
will be further elucidated as more information and data
are collected. Properly addressing this disease will require
careful consideration of the scientific facts, effective com-
munication with the public, and strategic planning by gov-
ernmental entities to ensure that the best possible health
outcomes will be realized.
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